Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $1.39 USD
Change Today +0.06 / 4.51%
Volume 47.9K
IMNP On Other Exchanges
Symbol
Exchange
NASDAQ CM
Stockholm
Frankfurt
Stockholm
As of 8:10 PM 08/28/15 All times are local (Market data is delayed by at least 15 minutes).

immune pharmaceuticals inc (IMNP) Snapshot

Open
$1.33
Previous Close
$1.33
Day High
$1.39
Day Low
$1.24
52 Week High
09/16/14 - $3.95
52 Week Low
08/24/15 - $1.05
Market Cap
38.4M
Average Volume 10 Days
177.0K
EPS TTM
$-1.57
Shares Outstanding
27.6M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for IMMUNE PHARMACEUTICALS INC (IMNP)

immune pharmaceuticals inc (IMNP) Related Bloomberg News

View More Bloomberg News

immune pharmaceuticals inc (IMNP) Related Businessweek News

No Related Businessweek News Found

immune pharmaceuticals inc (IMNP) Details

Immune Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops and commercializes targeted therapeutics for the treatment of inflammatory diseases and cancer. The company’s lead product candidate is Bertilimumab, a human monoclonal antibody, which is under Phase II clinical trial for the treatment of ulcerative colitis, bullous pemphigoid, and Crohn's disease. It is also developing AmiKet, a prescription topical analgesic cream, which is in Phase III clinical trial to treat peripheral neuropathies; NanomAbs technology platform, an antibody-drug conjugate platform for the treatment of cancer; and Crolibulin, a novel small molecule vascular disruption agent and apoptosis inducer, which is under Phase I/II clinical trials for the treatment of patients with solid tumors. The company has license, and other collaborative research and development arrangements with iCo Therapeutics Inc.; Yissum Research Development Company of The Hebrew University of Jerusalem Ltd.; MabLife SAS; Lonza Sales AG; Dalhousie University; Shire Biochem, Inc.; and Endo Pharmaceuticals. The company was founded in 2010 and is headquartered in New York, New York.

9 Employees
Last Reported Date: 04/15/15
Founded in 2010

immune pharmaceuticals inc (IMNP) Top Compensated Officers

Co-Founder, Chief Executive Officer and Direc...
Total Annual Compensation: $342.5K
Compensation as of Fiscal Year 2014.

immune pharmaceuticals inc (IMNP) Key Developments

Immune Pharmaceuticals, Inc. Announces Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2015

Immune Pharmaceuticals, Inc. announced unaudited consolidated earnings results for the second quarter and six months ended June 30, 2015. For the quarter, the company announced loss from operations of $2,808,000 compared to $3,021,000 for the same period a year ago. Net loss before income taxes was $2,876,000 compared to net income before income taxes of $260,000 for the same period a year ago. Net loss was $2,876,000 compared to net income of $260,000 for the same period a year ago. Net loss attributable to common stockholders was $2,931,000 compared to $412,000 for the same period a year ago. Basic and diluted net loss per common share was $0.12 compared to $0.03 for the same period a year ago. The increase in the net loss was due to a non-recurring derivative liability income of $3.5 million that was recorded in the second quarter of 2014, which offset the loss from operations. For the six months, the company announced loss from operations of $6,261,000 compared to $5,898,000 for the same period a year ago. Net loss before income taxes was $6,433,000 compared to $4,519,000 for the same period a year ago. Net loss was $6,433,000 compared to $4,519,000 for the same period a year ago. Net loss attributable to common stockholders was $8,248,000 compared to $5,239,000 for the same period a year ago. Basic and diluted net loss per common share was $0.34 compared to $0.37 for the same period a year ago.

Immune Pharmaceuticals, Inc. to Report Q2, 2015 Results on Aug 14, 2015

Immune Pharmaceuticals, Inc. announced that they will report Q2, 2015 results After-Market on Aug 14, 2015

Immune Pharmaceuticals, Inc. Presents at Virtual Investor Conference August 2015, Aug-06-2015 11:30 AM

Immune Pharmaceuticals, Inc. Presents at Virtual Investor Conference August 2015, Aug-06-2015 11:30 AM. Speakers: Daniel Gedeon Teper, Co-Founder, Chief Executive Officer and Director.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
IMNP:US $1.39 USD +0.06

IMNP Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Durect Corp $2.10 USD +0.08
View Industry Companies
 

Industry Analysis

IMNP

Industry Average

Valuation IMNP Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 2.7x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact IMMUNE PHARMACEUTICALS INC, please visit www.immunepharmaceuticals.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.